| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/14/2007 | EP1752465A2 Linear VH-CH1-VH-CH1 heavy chain antibody fragment |
| 02/14/2007 | EP1752189A2 Microprojection array having a beneficial agent containing coating |
| 02/14/2007 | EP1752163A1 Agent for actively restoring structure and functions of damaged tissues and organs |
| 02/14/2007 | EP1752160A2 Epitope sequences |
| 02/14/2007 | EP1752141A1 Immune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer |
| 02/14/2007 | EP1751291A1 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine |
| 02/14/2007 | EP1751290A2 Alphavirus replicon packaging constructs |
| 02/14/2007 | EP1751289A1 Tc-83-derived alphavirus vectors, particles and methods |
| 02/14/2007 | EP1751276A1 Vaccine comprising an attenuated pestivirus |
| 02/14/2007 | EP1751191A2 Antibodies to angiogenesis inhibiting domains of cd148 |
| 02/14/2007 | EP1751186A2 Carrier conjugates of tnf-peptides |
| 02/14/2007 | EP1751178A2 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| 02/14/2007 | EP1751174A1 Inhibitors of regiii proteins as asthma therapeutics |
| 02/14/2007 | EP1750772A1 Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
| 02/14/2007 | EP1750764A2 Antibodies of angiogenesis inhibiting domains of cd148 |
| 02/14/2007 | EP1750763A1 Method to reduce hepatotoxicity of fas-mediated apoptosis-inducing agents |
| 02/14/2007 | EP1750762A2 Methods for generating improved immune response |
| 02/14/2007 | EP1750761A1 Medical uses of carrier conjugates of non-human tnf-peptides |
| 02/14/2007 | EP1750760A1 Preservation by vaporization |
| 02/14/2007 | EP1750759A2 Screening method using antibody heavy chains |
| 02/14/2007 | EP1750749A2 Il-28 and il-29 cysteine mutants for treating viral infection |
| 02/14/2007 | EP1750747A1 Soluble lfa-3 polypeptide for treating viral disorders |
| 02/14/2007 | EP1750746A1 Methods of using il-1 antagonists to treat autoinflammatory disease |
| 02/14/2007 | EP1750707A1 Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and toll-like receptor 4 agonist |
| 02/14/2007 | EP1750670A1 Buccal, polar and non-polar sprays containing propofol |
| 02/14/2007 | EP1750500A2 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| 02/14/2007 | EP1417228B1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/14/2007 | EP1206495B1 Chimeric polypeptides, method for production and uses thereof |
| 02/14/2007 | EP1124959B1 Cell surface molecule-induced macrophage activation |
| 02/14/2007 | EP1066055B1 Horse DNA vaccines containing the adjuvant acrylic acid, methacrylic acid or EMA (R) |
| 02/14/2007 | EP1009413B1 Use of immunostimulatory oligonucleotides for preventing or treating asthma |
| 02/14/2007 | EP0833614B1 System and method for producing drug-loaded microparticles |
| 02/14/2007 | EP0662077B1 Cd27 ligand |
| 02/14/2007 | EP0522138B2 Influenza virus vaccine composition containing influenza virus core as an additive having a synergistic effect |
| 02/14/2007 | CN1914314A Method of producing virus |
| 02/14/2007 | CN1914227A Anti-MpI antibodies |
| 02/14/2007 | CN1914226A Antibodies against SARS-COV and methods of use thereof |
| 02/14/2007 | CN1913921A Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 02/14/2007 | CN1913920A Influenza immunogen and vaccine |
| 02/14/2007 | CN1913919A HIV vaccines based on env of multiple clades of hiv |
| 02/14/2007 | CN1913918A GM1 binding deficient exotoxins for use as immunoadjuvants |
| 02/14/2007 | CN1913882A Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids |
| 02/14/2007 | CN1912141A Identification of genes |
| 02/14/2007 | CN1912112A Recombinant infectious non-segmented negative strand rna virus |
| 02/14/2007 | CN1912111A Engomphosis and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen |
| 02/14/2007 | CN1912106A Dysentery multivalent genetic engineering vaccine and preparation method thereof |
| 02/14/2007 | CN1911965A Binding domain-immunoglobulin fusion proteins |
| 02/14/2007 | CN1911963A SARS neutralization antibody and application |
| 02/14/2007 | CN1911960A Chlamydia protein, gene sequence and uses thereof |
| 02/14/2007 | CN1911445A Grippe primary generation susliks kidney cell multivalent raccine and its preparation method |
| 02/14/2007 | CN1911444A Typhoid, paratyphoid ectoblast protein vaccine |
| 02/14/2007 | CN1911443A Vaccine composition comprising tumor antigen and adjunvant composition |
| 02/14/2007 | CN1300173C Human antibodies that bind huma TNF 'alpha' |
| 02/14/2007 | CN1300172C Immunoglobulin antibody against SARS-CoV and its preparing method |
| 02/14/2007 | CN1299771C Colorstrum-based composition |
| 02/14/2007 | CN1299769C Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof |
| 02/14/2007 | CN1299768C Preparation of diploid cell purified cerebritis B vaccine for human |
| 02/14/2007 | CN1299766C Use of TGF-beta and growth factor in treatment and prevention of intestinal mucosa diseases |
| 02/13/2007 | US7176299 Compounds |
| 02/13/2007 | US7176296 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| 02/13/2007 | US7176290 Tau protein epitopes for use in the treatment of alzheimer's disease |
| 02/13/2007 | US7176286 Antigen fragments for the diagnosis of Toxoplasma gondii |
| 02/13/2007 | US7176277 Conversion of apoptotic proteins |
| 02/13/2007 | US7176275 Peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating immune response; antisense agents |
| 02/13/2007 | US7176186 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
| 02/13/2007 | US7176180 Fusion proteins; immunoglobulins; kits |
| 02/13/2007 | US7176021 Mutant cells with altered sialic acid |
| 02/13/2007 | US7175996 Methods of optimizing antibody variable region binding affinity |
| 02/13/2007 | US7175988 Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| 02/13/2007 | US7175984 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds |
| 02/13/2007 | US7175849 Polypeptide for use in the treatment of viral disorders |
| 02/13/2007 | US7175848 Used to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS) |
| 02/13/2007 | US7175847 for the treatment of autoimmune disorders, and the prevention of organ rejection |
| 02/13/2007 | US7175846 Cancerous disease modifying antibodies |
| 02/13/2007 | US7175845 providing passive immunity against ricin intoxication in a subject |
| 02/13/2007 | US7175844 Administering an agent that inhibits a component of the VEGF signal transduction pathway; agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject. |
| 02/13/2007 | US7175842 Methods of modulating hair growth |
| 02/13/2007 | US7175839 Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
| 02/13/2007 | US7175838 Administering promoter of T-cell expansion and inducer of CD40 stimulation in synergistically effective amounts to treat or prevent pathologic state in mammal; cancer therapy |
| 02/13/2007 | CA2463976C N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| 02/13/2007 | CA2219947C Monoclonal antibody reactive to human cetp and assay method for human cetp |
| 02/13/2007 | CA2124958C Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
| 02/12/2007 | CA2553115A1 Modulation of peroxisome proliferation-activated receptors |
| 02/08/2007 | WO2008039171A2 Inactivating pathogens with hydrogen peroxide for vaccine production |
| 02/08/2007 | WO2007016606A2 Compositions and methods for modulating rank activities |
| 02/08/2007 | WO2007016598A2 Influenza vaccine compositions and methods of use thereof |
| 02/08/2007 | WO2007016591A2 Compositions and methods for monitoring and altering protein folding and solubility |
| 02/08/2007 | WO2007016590A2 Ovr232v3 antibody compositions and methods of use |
| 02/08/2007 | WO2007016556A1 Multifunctional polymers for promotion of opsonization of target cells and organisms |
| 02/08/2007 | WO2007016357A1 Amyloid beta receptor and uses thereof |
| 02/08/2007 | WO2007016340A2 Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| 02/08/2007 | WO2007016285A2 M-csf specific monoclonal antibody and uses thereof |
| 02/08/2007 | WO2007016240A2 Use of antibody to m-csf |
| 02/08/2007 | WO2007016214A2 Method for inhibiting tnf-alpha |
| 02/08/2007 | WO2007016185A2 Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
| 02/08/2007 | WO2007016130A2 A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
| 02/08/2007 | WO2007015841A2 A method for treating preeclampsia |
| 02/08/2007 | WO2007015569A1 Method for prediction of the efficacy of vascularization inhibitor |
| 02/08/2007 | WO2007015540A1 Cytotoxic t-cell epitope peptide and use thereof |
| 02/08/2007 | WO2007015441A1 Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration |